AVASTINTM(é¿ç¦æ¯æ±)
ï¼Bevacizumab)
ä»
ä¾éèå
使ç¨
ãè¦åã
èè ç©¿å/伤å£æå并åç
使ç¨é¿ç¦æ¯æ±å¯å¹¶åèè éç©¿åå伤å£å¼è£ï¼ææ¶çè³æ¯è´å½çãèè ç©¿åï¼ææ¶ä¼´æè
¹è
å
èè¿ï¼å¯åçå¨åºç¨é¿ç¦æ¯æ±çå
¨è¿ç¨(ä½å使ç¨æ¶é´çé¿ç没æç¸å
³æ§)ãé¿ç¦æ¯æ±åIFLéæ¨çåçèç¨æ¶ï¼èè ç©¿åçåçç为2%ã
æ ¹æ®æ¥éï¼å
¸åç表ç°ä¸ºè
¹çï¼ä¼´æ便ç§æååççç¶ãå¨åºç¨é¿ç¦æ¯æ±çè¿ç¨ä¸ï¼å¦ææ£è
åºç°è
¹çï¼åºèèèè ç©¿åçè¯æã
å¦ææ£è
å¨åºç¨é¿ç¦æ¯æ±çè¿ç¨ä¸åºç°èè ç©¿åæéè¦å»çå¹²é¢ç伤å£å¼è£ï¼é£é¿ç¦æ¯æ±åºæ°¸ä¹
åç¨ã为äºé¿å
é¿ç¦æ¯æ±æ²»çå½±å伤å£æå/伤å£å¼è£ï¼å¨åºç¨é¿ç¦æ¯æ±æ²»çç»æåè¦é´éå¤é¿æ¶é´åè¿è¡éæ©æ§ææ¯ï¼ç®åè¿æ²¡æå®è®ºã(è§è¦åï¼âèè ç©¿å/伤å£å¼è£ç»¼åçâåâåéåç¨æ³ï¼åéè°æ´â)
ãåºè¡é®é¢ã
严éçåºè¡ï¼ææ¶æ¯è´å½çãå¨åºç¨é¿ç¦æ¯æ±ååçèåæ²»çéå°ç»èèºçæ£è
ä¸åºç°åºè¡ï¼å¨ä¸ä¸ªå°åçéç¨é¿ç¦æ¯æ±ååçèåæ²»çéå°ç»èèºçç 究ä¸åç°ï¼ç
çç»ç»å¦ä¸ºé³çç严éæè´å½åºè¡åçç为31%ï¼èè
ºççåççä»
为4%ï¼ä½åç¬éç¨åççæ ä¸ä¾åçãè¿æåçè¿åºè¡çæ£è
ä¸åºæ¥åé¿ç¦æ¯æ±æ²»çã(è§è¦åï¼âåºè¡âåâåéåç¨æ³ï¼åéè°æ´â)ã
ãæ¦è¿°ã
é¿ç¦æ¯æ±(Bevacizumab)æ¯éç»ç人æºååå
éæä½ãéè¿ä½å
ãä½å¤æ£æµç³»ç»è¯å®IgG1æä½è½ä¸äººè¡ç®¡å
ç®çé¿å å(VEGF)ç»å并é»æå
¶çç©æ´»æ§ãèé¿ç¦æ¯æ±å
å«äºäººæºæä½çç»æåºåå¯ç»åVEGFçé¼ æºåæçäºè¡¥å³å®åºã
é¿ç¦æ¯æ±æ¯éè¿ä¸å½ä»é¼ åµå·¢ç»è表达系ç»ç产çï¼å
¶å¾ªç¯è¥å
»å¹å
»åºå
å«åºå¤§éç´ ãååé大约为149,000éå°é¡¿ãé¿ç¦æ¯æ±ä¸ºæ è²éæï¼æµ
ä¹³ç½è²æç°æ£è²ï¼PHå¼6.2çæ è液ä½ï¼ç¨äºéèè¾æ³¨ãé¿ç¦æ¯æ±æ100mgå400mg两ç§è§æ ¼ï¼å¯¹åºçä½ç§¯ä¸º4ml 16ml(25mg/ml)ï¼ä¸å«é²è
åï¼ä»¥ä¸æ¬¡æ§å°ç¶å
è£
ã100mgç产åç»ææ¯ï¼240mga-æµ·è»ç³äºæ°´ååç©ï¼23.2 mg磷é
¸é (å碱ï¼åæ°´ååç©)ï¼4.8 mg磷é
¸é (äºç¢±ï¼æ æ°´)ï¼1.6 mgå温20å注å°ç¨æ°´ï¼(ç¾å½ä¸å©)ã400mgç产åç»ææ¯ï¼960mga,a-æµ·è»ç³äºæ°´ååç©ï¼92.8 mg磷é
¸é (å碱ï¼åæ°´ååç©)ï¼19.2 mg磷é
¸é (äºç¢±ï¼æ æ°´)ï¼6.4 mgå温20å注å°ç¨æ°´ï¼(ç¾å½ä¸å©)ã
ã临åºè¯çå¦ã
ä½ç¨æºå¶
é¿ç¦æ¯æ±å¯ç»åVEGF并é²æ¢å
¶ä¸å
ç®ç»è表é¢çåä½(Flt-1åKDR)ç»åãå¨ä½å¤è¡ç®¡çæ模åä¸ï¼VEGFä¸å
¶ç¸åºçåä½ç»åå¯å¯¼è´å
ç®ç»èå¢æ®åæ°çè¡ç®¡å½¢æãå¨æ¥ç§äºç»è çç裸(æ è¸è
º)é¼ æ¨¡åä¸ï¼ä½¿ç¨é¿ç¦æ¯æ±å¯åå°å¾®è¡ç®¡çæ并æå¶è½¬ç§»ç
ç¶è¿å±ã
ãè¯ä»£å¨åå¦ã
é¿ç¦æ¯æ±çè¯ä»£å¨åå¦æ²çº¿ï¼åªæ£æµå
¶è¡æ¸
æ»æµåº¦(å³ä¸åºå游离çé¿ç¦æ¯æ±åç»åå°VEGFé
ä½ä¸çé¿ç¦æ¯æ±)ãåºäºä¸å®äººç¾¤çè¯ä»£å¨åå¦åæï¼491åæ£è
æ¥å1~20mg/Kgé¿ç¦æ¯æ±ï¼æ¯å¨1次ï¼æ¯2å¨1次ï¼ææ¯3å¨1次ï¼ä¼°è®¡é¿ç¦æ¯æ±çåè¡°æ大约为20天(èå´å¨11~50天)ãè¾¾å°ç¨³æçæ¶é´é¢è®¡ä¸º100天ãéç¨åé为10 mg/kgï¼æ¯2å¨1次çé¿ç¦æ¯æ±æ²»çæ¶ï¼å
¶è¡æ¸
è积ç为2.8ãé¿ç¦æ¯æ±çè¡æ¸
æ¸
é¤ä¸æ£è
çä½éãæ§å«åè¿ç¤è´è·çä¸åèææä¸åã
éè¿ä½éè¾æ£åï¼ç·æ§è¾å¥³æ§æè¾é«çæ¸
é¤ç(0.262 å/天 对. 0.207å/天)åè¾å¤§çæ¸
é¤ä½ç§¯(3.25 å对2.66 å)ãè¿ç¤è´è·å¤§ç(大äºæçäºè¿ç¤ä½è¡¨é¢ç§¯ä¸ä½å¼)æ£è
è¾è¿ç¤è´è·å°ç(å°äºè¿ç¤ä½è¡¨é¢ç§¯ä¸ä½å¼)æ£è
æè¾é«çæ¸
é¤ç(0.249å/天 对0.199å/天)ãå¨ä¸é¡¹813åæ£è
åå ç临åºéæºå®éªç 究ä¸ï¼æ²¡æè¯æ®è¯æï¼å¨åºç¨é¿ç¦æ¯æ±æ¶ï¼ç¸å¯¹äºå¥³æ§åè¿ç¤è´è·å°çæ£è
ï¼ç·æ§æè¿ç¤è´è·å¤§çæ£è
ççæå·®ã临åºçæä¸é¿ç¦æ¯æ±æ´é²éä¹é´çå
³ç³»ç®åè¿æ²¡æå®è®ºã
ãç¹æ®äººç¾¤ã
人å£ç»è®¡åææ°æ®æ示ï¼æ éå 为æ£è
çå¹´é¾ææ§å«ååéè°æ´ã
è¾åè½åææ£è
ï¼ç®åè¿æ²¡æé¿ç¦æ¯æ±å¨è¾æ害æ£è
ä¸çè¯ä»£å¨åå¦ç 究ã
èåä¸å
¨æ£è
ï¼ç®åè¿æ²¡æé¿ç¦æ¯æ±å¨èåä¸å
¨æ£è
ä¸çè¯ä»£å¨åå¦ç 究ã
ã临åºç 究ã
æ两个éæºç临åºç 究ç¨äºè¯ä»·é¿ç¦æ¯æ±èå以5-Fu为åºç¡çåçå¨æ²»ç转移æ§ç»ç´è çççæåå®å
¨æ§ãé¿ç¦æ¯æ±èåIFLæ¹æ¡éèæ¨æ³¨ã ç 究1æ¯ä¸ä¸ªåç²ãéæºç临åºç 究ï¼ç¨äºè¯ä»·é¿ç¦æ¯æ±å为转移æ§ç»ç´è ççä¸çº¿æ²»çãç
人éæºåé
å°ä¸ä¸ªç»ï¼ç¬¬1ç»ä¸ºIFLéæ¨+å®æ
°å(ä¼å©æ¿åº·125 mg/m2éæ¨ï¼5-æ°è²å§å¶ 500 mg/m2éæ¨ï¼åæ°¢å¶é
¸é20 mg/m2éæ¨ï¼æ¯å¨1次ï¼è¿ç¨4å¨ï¼6å¨ä¸º1å¨æ)ï¼ç¬¬2ç»ä¸ºIFLéæ¨+é¿ç¦æ¯æ±(5 mg/kgæ¯2å¨1次)ï¼ç¬¬3ç»ä¸º5-FU/LV+é¿ç¦æ¯æ±(5 mg/kgæ¯2å¨1次)ã
é¢å
å³å®ï¼å½IFLéæ¨+é¿ç¦æ¯æ±æ¹æ¡çæ¯æ§è¢«è¯ä»·ä¸ºå¯ä»¥æ¥åæ¶ï¼ç¬¬3ç»çå
¥ç»å³ä¸æ¢ã813åæ£è
被éæºåé
å°ç¬¬1ç»å第2ç»ï¼ä¸ä½å¹´é¾æ¯60å²ï¼40%为女æ§ï¼79%æ¯é«å 索人ï¼57%çæ£è
ECOGè¯å为0åï¼21%ååäºç´è ï¼28%æ¥åè¿è¾
å©åçï¼56%æ£è
ç主è¦ç
åé¨ä½ä½äºè
¹å¤ï¼38%æ£è
ç主è¦ç
åé¨ä½å¨èèãåç 究ç»ä¹é´æ£è
çå项ç¹æ§åºæ¬æ¯ç¸ä¼¼çã
å¾1ï¼ç 究1ççåæ²çº¿ã
两个主è¦å®éªç»è¿æ ¹æ®å
¶å¹´é¾ãæ§å«ã人ç§ãECOGè¯åãååè¿ç¤çé¨ä½ï¼æ¯å¦æ¥åè¿è¾
å©æ²»çï¼è½¬ç§»çé¨ä½ä»¥åè¿ç¤è´è·ç大å°åæä¸åçäºç»ï¼è¯ä»·å
¶æ¥åé¿ç¦æ¯æ±æ²»çç临åºåççã
å¨ç¬¬3ç»ç110åæ£è
ï¼ä¸ä½çåææ¯18.3æï¼ä¸ä½æ è¿å±çåææ¯8.8æï¼æ»ææçæ¯39%ï¼ä¸ä½ç¼è§£æ¶é´æ¯8.5æã
é¿ç¦æ¯æ±ä¸5-FU/LVèåç 究2ç 究1æ¯ä¸ä¸ªéæºç临åºç 究ï¼è¯ä»·é¿ç¦æ¯æ±ä¸5-FU/LVèåä½ä¸ºè½¬ç§»æ§ç»ç´è ççä¸çº¿æ²»çæ¹æ¡ãæ£è
被éæºåé
å°3个ç»ï¼ç¬¬1ç»ä¸ºæ¥åå纯5-FU/LVæ¹æ¡æ²»ç(5-æ°è²å§å¶ 500 mg/m2, åæ°¢å¶é
¸é 500 mg/m2 æ¯å¨1次ï¼è¿ç¨6å¨ï¼8å¨ä¸ºä¸å¨æ1)ï¼ç¬¬2ç»ä¸º5-FU/LVåçï¼é¿ç¦æ¯æ±5 mg/kg æ¯2å¨1次ï¼)第3ç»ä¸º5-FU/LVåçï¼é¿ç¦æ¯æ±10mg/kg æ¯2å¨1次ï¼æ£è
æ¥åæ²»çç´å°ç
æ
è¿å±ãé¦è¦çç 究ç»ç¹æ¯ææçåæ è¿å±çåæ
æ¥å5-FU/LVï¼é¿ç¦æ¯æ±5 mg/kgæ²»çç»å¨æ è¿å±çåææ¹é¢æ¾è好äºæªæ¥åé¿ç¦æ¯æ±æ²»çç»ãç¶èï¼å¨æ»çåæåæ»ææçæ¹é¢ï¼ä¸¤ç»ä¹é´æ æ¾èæ§å·®å¼ãèæ¥å5-FU/LVï¼é¿ç¦æ¯æ±10 mg/kgæ²»çç»å¨çææ¹é¢ä¸æªæ¥åé¿ç¦æ¯æ±æ²»çç»æ²¡æ¾èæ§å·®å¼ã
ãé¿ç¦æ¯æ±åè¯æ²»çã
ç®åï¼è¿æ²¡æé¿ç¦æ¯æ±åè¯æ²»çç»ç´è çççæç»æãç¶èï¼æä¸é¡¹æ£å¨è¿è¡çéæºç 究ï¼å¨æ¥å以5ï¼æ°è²å§å¶ï¼ä¼å©æ¿åº·ä¸ºåºç¡çåçä»è¿å±ç转移æ§ç»ç´è çæ£è
ï¼ç»äºåè¯é¿ç¦æ¯æ±æ²»çï¼ä½æ¤ç 究å åè¯é¿ç¦æ¯æ±æ²»çççæåçåææ¹é¢æ¯æ¥å以5ï¼æ°è²å§å¶ï¼åæ°¢å¶é
¸éï¼å¥¥æ²å©éçFOLFOXæ¹æ¡å·®è被ä¸æ¢ã
ãæ示åç¨éã
æ示ï¼é¿ç¦æ¯æ±èå以5ï¼æ°è²å§å¶ä¸ºåºç¡çåçæ¹æ¡ï¼å¯ç¨äºè½¬ç§»æ§ç»ç´è ççä¸çº¿æ²»çã
ãç¦å¿ã
ç®åè¿æ²¡æé¿ç¦æ¯æ±çç¦å¿è¯ã
ãè¯ç©ç¸äºä½ç¨ã
ç®åè¿æ²¡è¿è¡é¿ç¦æ¯æ±ä¸æè¿ç¤è¯ç©ç¸äºä½ç¨çæ£å¼ç 究ãå¨ç 究1ï¼æ£è
ç»äºä¼å©æ¿åº·/5-FU/CF(éæ¨IFL)èç¨æä¸èç¨é¿ç¦æ¯æ±ã
å¨å纯éæ¨IFLåèåé¿ç¦æ¯æ±æ¶ï¼ä¼å©æ¿åº·çæµåº¦æ¯ç¸åçãä½å¨IFLèåé¿ç¦æ¯æ±æ£è
ä¸ï¼ä¼å©æ¿åº·çæ´»æ§ä»£è°¢ç©SN38çæµåº¦æ¯å纯éæ¨IFLç»çæ£è
å¹³åé«åº33%ãå¨ç 究1ï¼éæ¨IFLèåé¿ç¦æ¯æ±è
åç3~4级è
¹æ³»åä¸æ§ç²ç»èéä½çåççé«ï¼ä½ç±äºå
¥ç»æ£è
çå¤æ ·æ§åæ ·åçæéæ§ï¼é¿ç¦æ¯æ±èåä¼å©æ¿åº·æè´çSN38æ°´å¹³åé«çå½±åç¨åº¦è¿ä¸æ¸
æ¥ã
è´çæ§ï¼è´çªåæ§å对çè²è½åçæ害ã ç®åè¿æ²¡æå
³äºé¿ç¦æ¯æ±å¯¹äººåå¨ç©è´çæ§çæ°æ®ãé¿ç¦æ¯æ±å¯è½æ害çè²è½åãæ10æ50mg/kgé¿ç¦æ¯æ±çåéè¿ç»ç»äºéæ§å¼¥ç´13æ26å¨ååç°åµå·¢åå宫çä½éï¼å宫å
èçå¢æ®ï¼æç»å¨ææ°éåå°ä»¥ååµæ³¡åè²é»æ»åé»ä½ç¼ºå¤±åå¨åéç¸å
³æ§ã
åè¯å¹¶ç»äº4~12å¨çæ¢å¤æ¶é´ï¼å¨é«åéç»è¿è¡äºæ£æ¥ï¼è®¡åæ¢å¤ç»ä¸ç两åªéæ§å¼¥ç´çæ£æ¥ç»ææ示æ害æ¯å¯éçã12å¨çæ¢å¤æåï¼åµæ³¡åè²é»æ»æ¶å¤±ï¼ä½åµå·¢ééä»æä¸ç度çåè½»ï¼å宫å
èçå¢æ®åå°æ¶å¤±ï¼ä½å宫ééçåå°ä»æ¯æ¾èçï¼2åªå¼¥ç´ä¸æ1åªä»æé»ä½ç¼ºå¤±åæç»å¨ææ°éåå°ï¼67%ï¼ã
ãå¦å¨ çå½±åã
以mg/kg为åä½ï¼å½ç»äºå®¶å
2åæ¨èåéçé¿ç¦æ¯æ±æ¶ä¼äº§çç¸å½¢ãè§å¯å°çå½±åå
æ¬æ¯äº²åèå¿ä½éçåå°ï¼èå¿æµäº§çå¢å ï¼åèå¿èº«ä½å骨è³åååçççå¢å ãææåéç»åè§å¯å°äºå¯¹èå¿çå½±åã
è¡ç®¡ççæ对èå¿çåè²æ¯è³å
³éè¦çãæ¥åé¿ç¦æ¯æ±æ²»çæè´çè¡ç®¡çæåå°æå¶å¯è½æ¯å¯¼è´å¦å¨ å¯ä½ç¨çåå ãä½å¨é¿ç¦æ¯æ±å¯¹å¦å¨ å¦å¥³çå½±åæ¹é¢ï¼è¿æ²¡æå
ååæè¯å¥½å¯¹ç
§ç临åºç 究ãåªæå¨å
åæè¡¡é¿ç¦æ¯æ±å¯¹èå¿æ½å¨å±é©çæ¶åï¼æè½è®©æåå¦å¥³å没æéåéå½çé¿åæªæ½çå¦å¥³æ¥åå
¶æ²»çãæææ£è
é½åºå¨æ²»çå¼å§ä¹å被åç¥é¿ç¦æ¯æ±å¯¹èå¿åè²çæ½å¨å±é©ã
å¦ææ£è
å¨æ¥åé¿ç¦æ¯æ±æ²»çè¿ç¨ä¸æåäºï¼å¥¹åºè¢«åç¥é¿ç¦æ¯æ±å¯¹èå¿çå±å®³åæµäº§çæ½å¨å±é©ãå³ä½¿æ¯åè¯çæ£è
ï¼å¥¹ä¹åºè¢«åç¥åè¯åç»çæ®çï¼é¿ç¦æ¯æ±çåè¡°æ大约为20天ï¼åå®å¯¹èå¿åè²çå¯è½å½±åã
ãåºä¹³æçæ¯äº²ã
ç®åè¿ä¸ç¥éé¿ç¦æ¯æ±æ¯å¦è½åæ³å°äººçä¹³æ±ä¸ãç±äºäººçIgG1æ¯è½åæ³å°äººçä¹³æ±ä¸çï¼å æ¤ç±äºå
¶å¯è½è¢«èå¿æååå¸æ¶æè´çå±å®³è¿ä¸å¾èç¥ãå æ¤ï¼å¨æ¥åé¿ç¦æ¯æ±æ²»çæ¶åå
¶åç»çæ®çæ¶é´ï¼èèå°äº§åçåè¡°æï¼å¤§çº¦ä¸º20天ï¼èå´å¨11~50天ï¼ï¼è¿æ®µæ¶é´å
åºåæ¢åºä¹³ã
ï¼è§ä¸´åºè¯çå¦ï¼è¯ä»£å¨åå¦ï¼
ãå°å¿ç使ç¨ã
ç®åè¿æ²¡æå
³äºé¿ç¦æ¯æ±å¯¹å°å¿æ£è
çå®å
¨æ§åçæçç 究ãä½å¨å¹¼å¹´å¼¥ç´ä¸ï¼ä½¿ç¨ä½äºæ¨èåéï¼ä»¥mg/kg为åä½ï¼çé¿ç¦æ¯æ±4å¨åï¼è§å¯å°äºåè²ä¸è¯ãåè²ä¸è¯çåççå严éæ§æ¯æåéç¸å
³çï¼ä½è³å°æä¸é¨åå¨åæ¢æ²»çåæ¯å¯ä»¥æ¢å¤çã
ãè年人ç使ç¨ã
å¨ç 究1ï¼ï¼æ ¹æ®ç¾å½å½ç«ççç 究ææ¯æ§æ åï¼åç3~4级å¯ä½ç¨ç人æ°çå
æ¬äºææåè¯è
ï¼396åIFLï¼å®æ
°åï¼392åIFLï¼é¿ç¦æ¯æ±ï¼109å5-FU/LVï¼é¿ç¦æ¯æ±ï¼ãä½åç1~2级å¯ä½ç¨ç人æ°åªå
æ¬äº309åäºç»åè¯è
ã
å æ¤æ²¡ææ¶éå°è¶³å¤çåç1~4级å¯ä½ç¨â¥65å²æ£è
æ ·æ¬æ°ä»¥è¯æèå¹´æ£è
åçæ»çå¯ä½ç¨æ
åµä¸éå¹´æ£è
ææä¸åã392åæ¥åIFLï¼é¿ç¦æ¯æ±æ²»ççæ£è
ä¸ï¼æ126åâ¥65å²ï¼è¿äºæ£è
å¨ç²ä¹æ åï¼è´¥è¡çï¼æ·±é¨è¡æ éèçï¼é«è¡åï¼ä½è¡åï¼å¿èæ¢å¡ï¼å
è¡æ§å¿åè¡°ç«ï¼è
¹æ³»ï¼ä¾¿ç§ï¼é£æ¬²åéï¼ç½ç»èåå°ï¼è´«è¡ï¼è±æ°´ï¼ä½é¾è¡çï¼ä½é è¡ çå¯ä½ç¨çåççæ¯<65å²çæ£è
é«ãå¨æ»çåææ¹é¢ï¼é¿ç¦æ¯æ±ççæå¨èå¹´ç»ä¸å¹´è½»ç»ç¸åã
å¨å
¥ç»Genentechèµå©å©ç临åºç 究ä¸ï¼è®°å½å°äº742åæ£è
åççææå¯ä½ç¨ãå
¶ä¸æ212 å(29%)æ¯å¹´é¾â¥65å²çï¼æ´æ43å(6%)æ¯å¹´é¾â¥75å²çãä»»ä½çº§å«çå¯ä½ç¨ï¼å¨èå¹´ç»ä¸çåççåæ¯å¹´è½»ç»é«ï¼æ£å¦ä¸é¢ææè¿°çï¼ææ¶åä¸è¯ï¼èè éåºè¡ï¼æ°´è¿ï¼é¼»è¡ï¼å³å½å éå声é³æ¹åã
ãå¯ä½ç¨ã
ä¸é¿ç¦æ¯æ±æå
³çæ严éçå¯ä½ç¨æï¼
èè ç©¿å/伤å£å¼è£ç»¼åçï¼è§è¦åï¼
åºè¡ï¼è§è¦åï¼
é«è¡åå±è±¡ï¼è§è¦åï¼
è¾ç
综åå¾ï¼è§è¦åï¼
å
è¡æ§å¿åè¡°ç«ï¼è§è¦åï¼
å¨1032åå
¥ç»Genentechèµå©ç临åºç 究并æ¥åé¿ç¦æ¯æ±æ²»ççæ£è
ä¸ï¼æ常è§ç严éå¯ä½ç¨æ¯ï¼è´«è¡ï¼ç¼çï¼é«è¡åï¼è
¹æ³»åç½ç»èåå°ã
èå¨742åå
¥ç»Genentechèµå©ç临åºç 究并æ¥åé¿ç¦æ¯æ±æ²»ççæ£è
ä¸ï¼å级å«ä¸æ常è§çå¯ä½ç¨æ¯ï¼è´«è¡ï¼ç¼çï¼è
¹çï¼å¤´çï¼é«è¡åï¼è
¹æ³»ï¼æ¶å¿ï¼ååï¼é£æ¬²åéï¼å£è
çï¼ä¾¿ç§ï¼ä¸å¼å¸éææï¼é¼»è¡ï¼å¼å¸å°é¾ï¼å¥è±æ§ç®çï¼èç½å°¿ã
ç±äºå¨ä¸´åºè¯éªç 究åå¨è®¸å¤ä¸åçæ¡ä»¶ï¼å æ¤å¨å®éªä¸è§å¯å°çæç§è¯ç©çå¯ä½ç¨åççä¸è½ä¸å¦ä¸è¯ç©çå¯ä½ç¨åççåç´æ¥æ¯è¾ãè临åºè¯éªæè·å¾çå¯ä½ç¨ä¿¡æ¯ä¹æ¯å¦æ¤ãä½æ¯ï¼å¯ä»¥å为é´å«è¯ç©ç¸å
³å¯ä½ç¨åå
¶åçççåºç¡ã
æ»å
±æ1032åæ£è
ï¼568å转移æ§ç»ç´è çå473åå
¶ä»è¿ç¤ï¼å
¥ç»Genentechèµå©ç临åºç 究并æ¥åäºé¿ç¦æ¯æ±æ²»çï¼åè¯æ²»çæ157åï¼ä¸åçèç¨æ875åãå
¶ä¸é¤å¤290åç742åæ£è
çææå¯ä½ç¨åææ¶éï¼ææçï¼NCI-CTCï¼3ã4级å¯ä½ç¨åææ¶éï¼è1ã2级å¯ä½ç¨ï¼å¦é«è¡åãèç½å°¿åè¡æ æ§äºä»¶ï¼æéæ©æ§å°æ¶éã
Genentechèµå©ç临åºå®éªç 究ä¸ææ¶éçå¯ä½ç¨å°ç¨äºå°æ¥ç¹å¼æ§å¯ä½ç¨çè¿ä¸æ¥é´å®ãï¼è§è¦åï¼åºè¡ï¼é«è¡åï¼èç½å°¿ï¼å
è¡æ§å¿åè¡°ç«å注æï¼è年人çåºç¨ãï¼å¯ä½ç¨ç对æ¯èµæï¼ç®åä»
éäºç 究1ï¼ä¸ä¸ª897åæ£è
åä¸çæ²»ç转移æ§ç»ç´è çççéæºç 究ã
æå¨äººååççå
¨é¨3ã4级å¯ä½ç¨åæéæ©çæäº1ã2级å¯ä½ç¨ï¼é«è¡åï¼èç½å°¿ï¼è¡æ æ§äºä»¶ï¼åææ¥éãå¨ç 究1ï¼ä¸ä½å¹´é¾æ¯60å²ï¼ç·æ§60%ï¼78%ååäºç»è ï¼29%æ¥åè¿è¾
å©ææ°è¾
å©åçãç 究1ï¼ç¬¬2ç»é¿ç¦æ¯æ±çä¸ä½æ´é²æ¶é´æ¯8个æï¼ç¬¬3ç»æ¯7个æãå¨ä¸ä¸ª309人çäºç»ä¸ï¼ææçå¯ä½ç¨ï¼å
æ¬1ã2级å¯ä½ç¨ï¼NCIï¼CTCï¼åææ¥éãè¿ä¸ª309人çå®å
¨æ§äºç»çå
¥ç»æ åä¸æ´ä¸ªç 究çå
¥ç»æ åæ¯ä¸æ ·çï¼å¹¶ä¸ä¸ä¸ªç 究å°ç»æå¾å¥½ç平衡ã严éçæå±èçå½çï¼NCIï¼CTC3ã4级ï¼å¯ä½ç¨ï¼å¨IFLéæ¨ï¼é¿ç¦æ¯æ±ç»çåççï¼2%ï¼è¾IFLéæ¨ï¼å®æ
°åç»é«ãè§è¡¨4ï¼
ãç®è¤ç²èåºè¡ã
å¨ç 究1ï¼æ¥åé¿ç¦æ¯æ±æ²»ççæ£è
严éæé严éåºè¡çåççåè¾é«(è§è¦åï¼åºè¡)ãå¨æ¶éç309ååç1~4级åºè¡çæ£è
ä¸ï¼é¼»åºè¡æ¯æ¯è¾æ®éçï¼IFLï¼é¿ç¦æ¯æ±ç»çåçç为35%ï¼èIFLï¼å®æ
°åç»çåççä»
为10%ãè¿ç±»å¯ä½ç¨ä¸è¬é½å¾è½»(NCI-CTC1级)ï¼æ éå¤çå°±å¯æ¢å¤ãèä¸äºè½»å°ä¸åº¦å¯ä½ç¨çåççå¨IFLï¼é¿ç¦æ¯æ±ç»é«äºIFLï¼å®æ
°åç»ï¼å
æ¬æ¶åéåºè¡(24% vs. 518 6%)ï¼å°ççé¾åºè¡(2% vs. 0)åé´éåºè¡(4% vs.2%)ã
ãè¡æ æ å¡ã
å¨ç 究1ï¼18%çIFLï¼é¿ç¦æ¯æ±ç»æ£è
å15%çIFLï¼å®æ
°åç»æ£è
åºç°3-4级çè¡æ æ å¡äºä»¶ãå¨ä¸å3-4级çè¡æ æ å¡åççå¨IFLï¼é¿ç¦æ¯æ±ç»é«äºIFLï¼å®æ
°åç»ï¼èè¡ç®¡äºä»¶(4 vs. 0 æ£è
)ï¼å¿èæ¢å¡(6 vs. 3)ï¼æ·±éèè¡æ (34 vs. 19),ï¼è
¹å
è¡æ å½¢æ(13 vs. 5)ãèä¸ä¹ç¸åçæ¯ï¼èºæ å¡çåççå¨IFLï¼å®æ
°åç»é«äºIFLï¼é¿ç¦æ¯æ±ç»(16 vs. 20)ã
å¨ç 究1ï¼392åæ¥åIFL+é¿ç¦æ¯æ±æ£è
ä¸æ53å(14%)å396åæ¥åIFL+å®æ
°åæ£è
ä¸ç30å(8%)åçè¡æ æ§äºä»¶èæ¥åå
¨åéçåæ³ä»¤æ²»çãæ¯ç»æ£è
ä¸åæ2å(å
±4å)å æ¤èåºç°åºè¡å¹¶åè¯ãèå¨2åæ¥åé¿ç¦æ¯æ±åå
¨åéåæ³ä»¤æ²»ççæ£è
ä¸ï¼æ¤ç±»äºä»¶ä¸ä»ä»¬åè¡åè½çå½é
æ ååæ¯å¼æå
³ãè¿53åæ¥åIFLï¼é¿ç¦æ¯æ±æ²»çæ£è
ä¸ç11å (21%)å30åä¸æ¥åIFLï¼å®æ
°åæ²»çæ£è
ä¸ç1å (3%)åºç°äºå次çè¡æ æ§äºä»¶ã
ãå
¶ä»ä¸¥éå¯ä½ç¨ã
ä¸å严éå¯ä½ç¨äºä»¶è¢«è®¤ä¸ºæ¯æ¥åç»èæ¯è¯ç©åççè¿ç¤æ£è
ä¸å¸¸è§ï¼èå¨é¿ç¦æ¯æ±ç临åºç 究ä¸è³å°æ1人åçã
躯ä½ï¼æµèç
æ¶åç³»ç»ï¼è æ¢é»ï¼è åæ»ï¼è ç³»èéèé»å¡ï¼å»åå£æºç¡å½¢æã
è¡æ¶²åæ·å·´ç³»ç»ï¼å
¨è¡ç»èåå°
代谢/è¥å
»æ§ç
çï¼ä½é è¡ç
æ³å°¿çæ®ç³»ç»ï¼è¾å°¿ç®¡åéã
ãè¿éã
é¿ç¦æ¯æ±çæ大èååéè¿ä¸æç¡®ãå¨äººç±»çæ大æµè¯åé为(20 mg/kg IV)ï¼16åæ£è
ä¸æ9ååºç°å¤´çï¼å
¶ä¸3å为严é头çã
åéåç¨æ³ æ¨èåé为5 mg/kgï¼ç¬¬14天ç»è¯1次ï¼éèè¾æ³¨ï¼ç´å°ç
æ
è¿å±ãå¨ä¸»è¦ææ¯å28天å
ä¸åºå¼å§é¿ç¦æ¯æ±æ²»çãå¼å§é¿ç¦æ¯æ±æ²»çåï¼ææ¯åå£åºå®å
¨æåã
ãåéè°æ´ã
ä¸æ¨è使ç¨é¿ç¦æ¯æ±æ²»çæ¶åå°åéãå¦æéè¦ï¼é¿ç¦æ¯æ±åºæå¦ä¸æ¹æ³åç¨æææ¶æ¨è¿ä½¿ç¨ã
æ£è
å¦æåºç°æ¶åéç©¿åï¼éè¦å»å¦å¤çç伤å£å¼è£ï¼ä¸¥éåºè¡ï¼è¾ç
综åå¾æé«è¡åå±è±¡åºæ°¸ä¹
åç¨ã æ£è
å¦æåºç°éè¿ä¸æ¥æ£æµæå³å®çä¸å°é度èç½å°¿åå»å¦å¤çå°æªæ§å¶ç严éé«è¡ååæ¨èææ¶æ¨è¿ä½¿ç¨ãå¨ä¸å°é度èç½å°¿æ£è
继ç»ä½¿ç¨æææ¶æ¨è¿ä½¿ç¨é¿ç¦æ¯æ±çå±é©æ§å°æªæç¡®ãå¨éæ©æ§ææ¯åï¼é¿ç¦æ¯æ±åºææ¶åç¨å å¨ã(è§è¦åï¼æ¶åéç©¿å/伤å£æå并åè¯åé¢é²ï¼ææ¯)ãåºå¨ææ¯åå£å®å
¨æååæè½éæ°å¼å§ä½¿ç¨é¿ç¦æ¯æ±ã
ã使ç¨ååå¤ã
é¿ç¦æ¯æ±åºéè¿ä¸ä¸å«ç人åéç¨æ èææ¯ç¨éåæè¾æ³¨ãæ5 mg/kgçåéæ½åæéçé¿ç¦æ¯æ±ï¼ç¨éå°æ»ä½ç§¯ä¸º100 mLç0.9%æ°¯åé 注å°æ¶²
ï¼(ç¾å½ä¸å©)ãç±äºäº§åæªå«é²è
åï¼åºæå¼å°ç¶ä¸çå©ä½é¨åãå为注å°ç¨è¯ç©ï¼å¨ä½¿ç¨åï¼åºèç¼è§å¯ææ é¢ç²ç©è´¨ååè²ã
ç¨éåçé¿ç¦æ¯æ±æº¶æ¶²åºå¨2-8°ç¯å¢ä¸ä¿åï¼æé¿å¯è¾¾8å°æ¶ãé¿ç¦æ¯æ±ä¸èæ°¯ä¹ç¯åèç¯çè¢æ²¡æä¸ç¸å®¹ã
é¿ç¦æ¯æ±ä¸åºä½¿ç¨ç³æº¶æ¶²é
å¶æä¸ç³æº¶æ¶²æ··åã
ã使ç¨ã
é¦æ¬¡åºç¨é¿ç¦æ¯æ±åºå¨åçåéèè¾æ³¨90åé以ä¸ãå¦æ第ä¸æ¬¡è¾æ³¨èåè¯å¥½ï¼ç¬¬äºæ¬¡è¾æ³¨å¯ä¸º60åç§ä»¥ä¸, ãå¦æ60åéä¹èåè¯å¥½ï¼ä»¥åçè¾æ³¨å¯æ§å¶å¨30åé以ä¸ã
ã稳å®æ§åä¿åã
é¿ç¦æ¯æ±åºä¿åå¨2-8°çå°ç®±ä¸ï¼é¿å
ä¿åäºåå
ç纸箱ä¸ç´å°ä½¿ç¨ã
å
è£
ï¼æ4mlå16ml两ç§è§æ ¼ï¼ä¸ºç½®äºä¸æ¬¡æ§ç»çç¶ä¸çæ è溶液ï¼æ¯ç¶åå«å«100 å400 mg çBevacizumabã å个100 mgå
è£
ï¼å«æä¸ç¶4mlçé¿ç¦æ¯æ±ã(25 mg/mL). NDC 50242-060-01 606 å个400 mgå
è£
ï¼å«æä¸ç¶16mlçé¿ç¦æ¯æ±ã(25 mg/mL). NDC 50242-060-02 608ã
åèæç®ï¼ 1. Presta LG, Chen H, O\'\'\'\'\'\'\'\'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. 人æºåçæè¡ç®¡å
ç®çé¿å ååä½çåå
éæä½ç¨äºæ²»çå®ä½ç¤åå
¶ä»ç
çãCancer Res 1997;57:4593-9.
Avastinè·åä½ä¸ºææç»è çäºçº¿æ²»çè¯ (2006-6-22)
çç©å¶è¯å
¬å¸Genentechå¨6æ20æ¥ç§°ï¼FDAå·²æ¹åAvastinçæ©å¤§éåºçï¼å³ä½ä¸ºææç»è ççäºçº¿æ²»çè¯ç©ã
æ¤åï¼Avastin+åçèç¨å·²è·åä½ä¸ºææç»è ççä¸çº¿æ²»çè¯ã
åèèµæï¼http://baike.baidu.com/view/1543699.htm